GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.

Background: GPR119 is a Gαs-protein-coupled receptor expressed predominantly in pancreatic islets and gastrointestinal tract in humans.

Objective/methods: To review the available literature on GPR119 agonists.

Results: GPR119 de-orphanisation indicates two classes of possible endogenous agonists, phospholipids and fatty acid amides, with oleoylethanolamide and N-oleoyldopamine being the most potent.